Pitch Competition

Farmio is a Singapore-based AI-native food supply chain platform serving businesses across Asia. We help food businesses streamline sourcing, procurement, inventory, logistics, finance, and cross-border trade through AI-powered automation.

Farmio currently serves more than 3,000 F&B and food-related businesses across Singapore and Hong Kong, including restaurants, hotels, bakeries, retailers, and food manufacturers. We facilitate hundreds of millions of dollars in annual food trade across products including eggs, rice, oil, and fresh produce.

Our AI-native operating system integrates proprietary AI agents into existing workflows and communication channels such as WhatsApp. Over 70 operational workflows can be automated, including order processing, demand forecasting, inventory management, supplier coordination, invoicing, payment tracking, logistics planning, and customer support. This helps businesses reduce manual work, improve procurement efficiency, and gain greater supply chain visibility without the complexity of traditional ERP systems.

Farmio also connects buyers, suppliers, logistics providers, financial institutions, and other supply chain partners, enabling more efficient and transparent food trade across the region.

Please contact us if there any questions or clarifications needed. We are very excited for the opportunity to participate in this event.

AironWorks brings together world-class AI researchers and ethical hackers to provide organizations with a “cyber vaccine.”

With most phishing attacks now generated by AI, attack techniques are evolving every day like new viral variants. Annual security training alone is no longer enough to build lasting immunity.

Our team of frontline ethical hackers, who understand attacks from the attacker’s perspective, works alongside our AI research team to recreate real-world attacks in a safe, harmless environment—delivering “real attacks” tailored to each individual employee.

By analyzing how employees respond, we build their antibodies: lasting behavioral change that strengthens their ability to recognize and resist attacks.

Our AI agents also continuously monitor incoming emails, helping organizations respond to threats as they emerge and maintain business continuity (BCP) when incidents occur.

To date, we have provided our services to 1,400 organizations and 700,000 users across more than 20 countries.

TopoLogic is developing a memory technology to solve the biggest “Memory Wall” in AI computing, cach e memory. With 4x capacity increase over existing cache memory technologies, TopoLogic’s TL-RAM helps deliver unprecedented AI processor performance by enabling processors that process more parameters, and more parallel computing nodes, which is critical for today’s AI chip performance. By utilizing topological antiferromagnets, a novel material technology researched by the University of Tokyo, To poLogic is developing memory cells that are based on magnetic memory but operate at cache memory spe

eds, meaning substantially smaller cell size. This allows chip designers to place several hundreds of MBs~GB range cache memory directly on-chip. This technology aims to fundamentally increase the program size and parameter size of AIs by a substantial margin.

A deep-tech startup originating from Stanford University, headquartered in Tokyo, Japan. Founded to commercialize wireless power transfer technology born from research on miniaturizing cardiac pacemakers, to treat diseases medicine alone cannot cure. Funding to date: approx. USD 45M.

Every technological revolution, from printing to steam to the internet, did one thing: structurally reset the cost of something the world already did. Wiring and batteries are what make sensing the physical world expensive. Removing them collapses the cost of capturing physical data and redefines how far Physical AI can scale.

Aeterlink pioneered the world’s first practical spatial wireless power transfer solution, AirPlug™, now deployed in Factory Automation (FA), Building Management (BM), and medical implants. In FA, lines run on countless cabled sensors, and one disconnection halts the line; fully wireless sensors, already in mass production, remove that failure mode. In BM, mass-produced temperature and humidity sensors enable automatic HVAC control that cuts electricity costs and improves comfort.

With the vision of a wiring-free digital world, Aeterlink continues to expand globally.

Nicslab is a deep-tech company developing advanced electronic and photonic integrated solutions for next-generation data centers, AI, and quantum computing. We address a critical bottleneck in scaling complex optical systems: precise, high-density, and cost-efficient control of increasingly complex photonic devices.

Our patented high-density multichannel technology delivers up to 20× more compact and 3× lower-cost solutions than conventional approaches, enabling customers to control more channels while reducing system size, complexity, and infrastructure cost.

Nicslab has shipped products to more than 100 customers across 24 countries, including NVIDIA, Fujitsu, NASA, leading universities, and global research laboratories. With proprietary chip-scale technologies and a growing international footprint, Nicslab is building the enabling infrastructure to scale integrated photonics from R&D into high-volume commercial applications.

Kyoto Fusioneering is the world’s premier fusion technology and integrated systems developer. It delivers plasma heating, tritium fuel cycle, and tritium breeding blanket and thermal cycle systems that advanced fusion programs worldwide depend on, regardless of confinement approach. KF operates globally across Japan, the United States, the United Kingdom, Germany, and Canada. Visit us at kyotofusioneering.com.

LINEA Innovations is a Tokyo-based fusion energy company founded in 2023, developing a commercial reactor fueled by hydrogen and boron-11 (p-11B). Unlike mainstream deuterium-tritium fusion, p-11B needs no radioactive tritium fuel cycle and produces very few neutrons, reducing material activation and enabling a simpler, compact plant that can be sited close to demand.

Our approach combines an FRC-Mirror hybrid configuration with beam-driven, non-thermal fusion reactions. It builds on the research assets and expertise of Nihon University and the University of Tsukuba, where our co-founding CSO and CTO lead research on FRC and mirror fusion. Our core business is the manufacture, sale and maintenance of commercial fusion reactors for power utilities, hyperscale data centers and industrial sites. In parallel, we are pursuing near-term revenue by commercializing our plasma, beam and high-energy technologies in adjacent fields such as industrial plasma ion sources.

In August 2026, our project was conditionally selected for Japan’s METI fusion power generation demonstration subsidy. We are advancing toward power generation demonstration in the 2030s.

Liquium’s ammonia catalysts mark a new frontier in ammonia production, promoting a pathway to increase productivity and energy efficiency in how we make ammonia today and in the future. Specifically, Liquium is optimising the Haber-Bosch process. This will increase the output and efficiency of existing global ammonia facilities and, in turn, unlock greater-scale production in new low-carbon ammonia plants, enabling ammonia to become the dominant zero-carbon fuel for the maritime and power generation sectors. Liquium is actively working with global leaders across our value chain, from raw material suppliers to specialist global engineering companies and end users. This means Liquium is scaling up what we do: catalyst development and fabrication, and ammonia production pilot trials. We are proving the technology with partners so we can bring a certifiable, warrantable new catalyst product to the world’s largest synthetic chemical. This innovation is needed to resolve an impending ammonia shortfall and unlock a clean fuel to decarbonise a fossil-fuel world.

Periotherapia is a clinical-stage biotech company spin out of The University of Osaka, developing a new approach to one of the biggest unsolved challenges in cancer treatment: drug resistance. Based on long-term research by our founder, Professor Yoshiaki Taniyama, we identified pathological periost in as an important driver of the protective tumor microenvironment (TME). Our lead antibody, PT0101, is a first-in-class therapy designed to selectively target this pathological form of periostin. By weakening the protective stromal barrier around tumors, PT0101 aims to overcome treatment resistance and restore sensitivity to existing anticancer therapies. A Phase 1/2a study is ongoing in Japan. We aim to establish clinical proof of concept first in breast cancer, then expand PT0101 to other sol id tumors and combinations with a broad range of anticancer therapies. Our business model is to build a strong clinical and biomarker data package, then pursue licensing or co-development with global pharmaceutical companies for late-stage development and commercialization.

AiRato Inc. is a deep-tech SaMD startup driven by a singular mission: to save every cancer patient through advanced radiotherapy. Currently, global shortages of specialized oncologists mean that optimal care is not reaching patients whose lives could otherwise be saved.

In advanced treatments like IMRT, precise planning is a massive bottleneck, requiring up to 6 hours of skilled manual labor. Our Class III approved platform, “RatoEra,” automates this workflow down to 20 minutes through two core advantages: (1) world-class AI technology and R&D engine, backed by our founder who leads Japan’s largest radiotherapy research lab, and (2) world-leading “Made in Japan” treatment planning data with millimeter-level precision.

Starting with our approved 1st-generation product, we will expand our platform every two years with features that directly enhance therapeutic efficacy, driving continuous upselling.

Already testing with 25 leading facilities across Japan and Southeast Asia, AiRato is expanding into the US market to build the global digital infrastructure for modern radiotherapy

Pushing the boundaries of medicine and wellness, developers have begun to explore more potent and precise active molecules like peptides, proteins and RNAs. The biggest challenge for these molecules is not in What to Use but rather How to Use them? How to keep them stable, How to administer enough dose, How to concentrate efficacy and avoid off-targets? Jay Sarkar (Stanford PhD) and Akira Yamamoto (SRI veteran) overcame these obstacles for specific use cases in the prior startups they founded and exited. They now lead the Silicon Valley startup reThink64 around a broader solution. Their novel “NanoEmitters” stably store a multitude of actives on the shelf. Then once applied in/on the body, they package and emit the active in a stream of daughter nanoparticles, for penetrating and concentrated delivery. In just 4 years, reThink64 has achieved live animal and human validation, and its initial revenue through sponsored co-development and out-licensing with commercial clients (including a large strategic in Japan). They are rapidly growing with partners in the US, Europe and Asia, to position themselves as the key enabling technology for the next generation of drugs and cosmetics.

bitBiome is a pioneering biotechnology start-up poised to revolutionize the global bio-manufacturing industry through the strategic convergence of proprietary microbial genomics, high-throughput biology, and advanced artificial intelligence. With an overarching mission to “unlock the full potential of microbes,” bitBiome is fundamentally shifting the field of synthetic biology from an era of empirical, trial-and-error experimentation into a highly predictive, data-driven engineering discipline. Having established a diverse, internationally experienced commercial team across Tokyo, the United States, and the United Kingdom, bitBiome is uniquely positioned to deliver “Generative AI” moments in biology and collaborate with companies from food, flavor and fragrance, chemical, pharma and animal health. bitBiome is the only Japanese biotechnology company whom I-Q-T, a renowned US strategic investor, invested in.

BioBytes Inc. is a physician-founded digital health and biotechnology company specializing in sarcopenia, a major cause of falls, disability, and loss of independence in aging populations. Our flagship platform, MyoTest, combines AI-based video analysis of gait, balance, and chair-stand performance with clinical data and biomarkers to enable objective, scalable screening and personalized monitoring without specialized motion-analysis equipment. Our core competitive advantage is M-Bank, a 15-year prospective sarcopenia cohort and biobank integrating longitudinal clinical assessments, physical-function data, blood and muscle tissue samples, and multi-omics data. This proprietary infrastructure enables BioBytes to connect real-world patient assessment with biomarker validation and therapeutic-target discovery. Founded by an orthopedic surgeon and developed with clinical and biotechnology experts, BioBytes provides an integrated platform spanning early detection, precision intervention, and drug discovery. MyoTest is already being used in more than 30 clinics, with hospital validation and medical-device regulatory development underway.

EF Polymer is a Japan-based startup developing and manufacturing natural, biodegradable superabsorbent polymers from upcycled fruit peels, such as oranges and bananas.

Through our proprietary technology, we upcycle fruit-derived materials into agricultural inputs that retain and gradually release water in soil. This improves water-use efficiency for crops while helping reduce irrigation requirements, as well as the costs and labor associated with farming.

We have sold approximately 1,000 tons across more than 10 countries, primarily in Japan, India, the US, and Europe.

Beyond agriculture, we are expanding our business into cosmetics, daily-use consumer products, and other fields where alternatives to petroleum-derived polymers are increasingly needed.

Born in India and Okinawa, Japan, EF Polymer is bringing its circular material technology to global markets.

A-SEEDS Co., Ltd. is a clinical-stage biotechnology company developing next-generation, non-viral CAR-T cell therapies for acute myeloid leukemia (AML) and solid tumors, where no CAR-T therapies are currently approved. Our proprietary platform is powered by the piggyBac transposon and combines three key design advantages: memory-rich CAR-T cells designed for durable antitumor activity, tumor-selective targeting for AML, and dual-antigen targeting for solid tumors to reduce antigen escape. A-SEEDS is advancing two clinical-stage programs: GMR CAR-T for AML and EPHB4 CAR-T for solid tumors, with Phase 1 studies underway in Japan and Australia and future global Phase 2 development planned. Our business model creates value through both proprietary pipeline licensing and CAR-T platform licensing to global pharmaceutical and biotechnology companies.